Skip to content

High-risk HPV infection raises HIV risk at least fourfold: HPV vaccine study suggested

Lopinavir/ritonavir cost-effective first-line after single-dose nevirapine in South Africa

Once-daily Kaletra as safe and effective as twice-daily dosing

English government considering revising policy on charging foreign nationals for HIV treatment

`Test and treat` unlikely to halt Washington epidemic

Cost of ART delivery in Malawi affordable within WHO-recommended health budget

Two new analyses add to abacavir cardiovascular risk debate

DART study shows HIV treatment without lab monitoring safe, effective in Africa

US officials outline Obama administration's AIDS policy